Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

SEC Filings

Form 10-Q
SERES THERAPEUTICS, INC. filed this Form 10-Q on 05/09/2018
Document Outline
Entire Document (4310 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - Seres Therapeutics, Inc.
Page 3 - FORWARD-LOOKING STATEMENTS
Page 4 - PART I FINANCIAL INFORMATION
Page 5 - SERES THERAPEUTICS, INC.
Page 6 - SERES THERAPEUTICS, INC.
Page 7 - SERES THERAPEUTICS, INC.
Page 8 - Unaudited Interim Financial Information
Page 9 - Recently Issued Accounting Standards
Page 10 - Restricted Cash
Page 11 - N/A
Page 12 - Stock Options
Page 13 - Restricted StockUnits
Page 14 - Financial Statement Impact of Adopting ASC 606
Page 15 - Revenue Recognition
Page 16 - Milestone Payments:
Page 17 - License and Collaboration Arrangements
Page 18 - Leases
Page 19 - Mazurek v. Seres Therapeutics, Inc., et.al.,
Page 20 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations.
Page 21 - N/A
Page 22 - Financial Operations Overview
Page 23 - Research and Development Expenses
Page 24 - Other Income (Expense), Net
Page 25 - Revenue
Page 26 - Liquidity and Capital Resources
Page 27 - Investing Activities
Page 28 - Contractual Obligations and Commitments
Page 29 - Off-Balance Sheet Arrangements
Page 30 - PART II - OTHER INFORMATION
Page 31 - We will need additional funding in order to complete development of our product candidates and comme
Page 32 - Our limited operating history may make it difficult to evaluate the success of our business to date
Page 33 - Our product candidates are based on microbiome therapeutics, which is an unproven approach to therap
Page 34 - N/A
Page 35 - If we experience delays or difficulties in the enrollment of patients in clinical trials, our receip
Page 36 - A Fast Track designation by the FDA may not actually lead to a faster development or regulatory revi
Page 37 - We may seek orphan drug designation for some of our product candidates, but may not be able to obtai
Page 38 - We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those
Page 39 - We have no experience manufacturing our product candidates at commercial scale, and if we decide to
Page 40 - If we are unable to establish effective sales, marketing and distribution capabilities or enter into
Page 41 - Even if we are able to commercialize any product candidates, the products may become subject to unfa
Page 42 - Product liability lawsuits against us could cause us to incur substantial liabilities and limit comm
Page 43 - Failure to obtain marketing approval in international jurisdictions would prevent our product candid
Page 44 - Our relationships with customers, physicians and third-party payors will be subject to applicable an
Page 45 - Recently enacted and future legislation may increase the difficulty and cost for us to obtain market
Page 46 - N/A
Page 47 - Governments outside the United States tend to impose strict price controls, which may adversely affe
Page 48 - Third parties may initiate legal proceedings alleging that we are infringing their intellectual prop
Page 49 - If we are unable to protect the confidentiality of our trade secrets and know-how, our business and
Page 50 - Association for Molecular Pathology v. Myriad Genetics, Inc.Alice Corp. v. CLS Bank InternationalMay
Page 51 - Issued patents covering our product candidates could be found invalid or unenforceable or could be i
Page 52 - Obtaining and maintaining our patent protection depends on compliance with various procedural, docum
Page 53 - If our trademarks and trade names are not adequately protected, then we may not be able to build nam
Page 54 - Risks Related to Our Operations
Page 55 - A variety of risks associated with operating internationally could materially adversely affect our b
Page 56 - We have been subject to securities class action litigation and may be subject to similar or other li
Page 57 - Risks Related to Our Common Stock
Page 58 - A significant portion of our total outstanding shares are eligible to be sold into the market, which
Page 59 - Provisions in our restated certificate of incorporation and amended and restated bylaws and under De
Page 60 - Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Page 61 - Item 6. Exhibits.
Page 62 - SIGNATURES
Subdocument 2 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 3 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 4 - EX-32.1 - EX-32.1
Page 1 - N/A
Subdocument 5 - EX-32.2 - EX-32.2
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer